Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Top Cited Papers
- 24 December 2014
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 122 (4), 809-816
- https://doi.org/10.1016/j.ophtha.2014.11.007
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT)Ophthalmology, 2013
- Optical Coherence Tomography Grading Reproducibility during the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical TrialsOphthalmology, 2011
- An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillarisProceedings of the National Academy of Sciences of the United States of America, 2009
- CFH, C3 and ARMS2 Are Significant Risk Loci for Susceptibility but Not for Disease Progression of Geographic Atrophy Due to AMDPLOS ONE, 2009
- The Epidemiology of Progression of Pure Geographic Atrophy: The Beaver Dam Eye StudyAmerican Journal of Ophthalmology, 2008
- Toll-like Receptor 3 and Geographic Atrophy in Age-Related Macular DegenerationThe New England Journal of Medicine, 2008
- The Long-term Natural History of Geographic Atrophy from Age-Related Macular Degeneration: Enlargement of Atrophy and Implications for Interventional Clinical TrialsOphthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006